Form 8-K Oncothyreon Inc. For: Sep 22
Tweet
Share
E-mail
http://archive.fast-edgar.com/20140923/AT22B22FZZ2RK2Z222JM2MXQGBMN4Z223262
Filed on: September 23, 2014
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Motel 6 Receives Franchisees' Choice Designation for the Fourth Year in a Row
- Annual PA Compensation Continues Rising, Increases 5.8% Over 2022
- Exegenesis Bio to Present 9-Patient Data from a Phase 1/2 Clinical Trial of EXG001-307, a Novel rAAV Gene Therapy for Spinal Muscular Atrophy (SMA) Type 1: Improved Head Control and Sitting Without Ex
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
